Comparison of Nasal Steroids After FESS in CRSwNP

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare intranasal fluticasone spray with budesonide nasal saline rinses in both the upright and head forward positions in patients who have had functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis with nasal polyposis (CRSwNP) and measure differences in Sinonasal Outcome Test-22 (SNOT-22) scores and Lund- Kennedy scores on rigid nasal endoscopy at time points 1 week, 3 weeks, 6 weeks, 2 months, 4 months, and 6 months post-op.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Budesonide Nasal Instillation in a Vertex-to-floor Position

NCT02862509

Chronic Frontal Rhinosinusitis Vertex to Floor Position

UNKNOWN PHASE2

The Role of Budesonide Intrapolyp Injection in CRSwNP

NCT05474924

CRS Polyp, Nasal

UNKNOWN PHASE4

The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery

NCT02562924

Chronic Sinusitis Nasal Polyposis

COMPLETED NA

Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates

NCT03519061

Chronic Sinus Infection Chronic Sinusitis Chronic Sinusitis - Ethmoidal, Posterior +1 more

WITHDRAWN PHASE2/PHASE3

Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients

NCT03303677

Chronic Rhinosinusitis (Diagnosis)

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic rhinosinusitis (CRS) is an inflammatory condition of the lining of the nose and sinuses that lasts 12 weeks or longer with objective evidence of mucosal inflammation (1). CRSwNP is characterized by the presence of bilateral nasal polyps in the middle meatus. Patients with CRSwNP for whom medical therapy has failed, often have functional endoscopic sinus surgery.

Nasal steroids are important post-operatively to prevent polyps from recurring. Many studies have shown that nasal steroids are superior to placebo in maintaining improvement in symptom scores, such as SNOT-22, post-operatively by preventing polyps from returning (2). Nasal steroids can reduce inflammation locally and can prevent disease relapse without the systemic effects of oral steroids. However, there is no consensus as to which nasal steroid and which delivery method is most effective in treating these patients. Traditional nasal sprays, such as fluticasone spray, may not deliver the medication widely in the nasal cavity. Budesonide is available in a respule form that can be used to instill the medication in the nose. In an attempt to more effectively deliver the medication, changes in patient's head position has been prescribed to achieve better delivery (3). The safety of intranasal budesonide, a more potent steroid than fluticasone, has been established (4, 5). However, any improved efficacy over fluticasone nasal spray remains anecdotal as head to head comparisons have not previously been performed.

Practice patterns among rhinologists in the post-operative prescription of nasal steroids vary widely. Determining which medication/delivery method is more effective will help rhinologists better treat their patients and prevent symptoms, for which the surgery was performed, from returning.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinusitis Nasal Polyps

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fluticasone nasal spray

Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)

Group Type ACTIVE_COMPARATOR

fluticasone nasal spray

Intervention Type DRUG

use 2-50 mcg sprays to each nostril two times per day

budesonide respule in head upright

Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day

Group Type ACTIVE_COMPARATOR

Budesonide head upright

Intervention Type DRUG

(0.5 mg/2mL) to instill into each nostril in the upright position two times per day

budesonide head forward

Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.

Group Type ACTIVE_COMPARATOR

Budesonide head forward

Intervention Type DRUG

(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluticasone nasal spray

use 2-50 mcg sprays to each nostril two times per day

Intervention Type DRUG

Budesonide head upright

(0.5 mg/2mL) to instill into each nostril in the upright position two times per day

Intervention Type DRUG

Budesonide head forward

(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

fluticasone propionate nasal Flonase budesonide pulmicort respules budesonide pulmicort respules

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who have had FESS for CRSwNP within the study period

Exclusion Criteria

1. Patients who are under the age of 18
2. Concurrent oral corticosteroid use of the equivalent of greater than 10 mg of prednisone use per day
3. The use of medications that accelerate the clearance of systemic cortisol (Dilantin, rifampin, amphetamines, and lithium)
4. The use of medications that inhibit the clearance of systemic cortisol (ketoconazole, amphotericin B, bupropion, fluoroquinolones)
5. Known hypersensitivity to corticosteroids
6. A personal history of Wegener's Granulomatosis or other autoimmune disease with nasal manifestations

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No